XML 71 R62.htm IDEA: XBRL DOCUMENT v3.21.2
Loan Payable to Silicon Valley Bank (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended
Apr. 23, 2020
Apr. 02, 2020
Oct. 17, 2019
Feb. 21, 2017
Sep. 30, 2021
Sep. 30, 2020
Jun. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Mar. 23, 2017
Short-term Debt [Line Items]                    
Amortization of deferred financing costs               $ 46,000 $ 80,000  
Interest rate         3.25%     3.25%    
Gain on extingushment of debt           $ 1,141,000  
Warrant [Member]                    
Short-term Debt [Line Items]                    
Warrants to purchase, shares       8,247           7,321
Warrant exercise price, per share       $ 4.85           $ 5.46
Amended Loan Agreement [Member]                    
Short-term Debt [Line Items]                    
Line of credit, description     Oncocyte may prepay in full the outstanding principal balance at any time, subject to a prepayment fee equal to 2.0% of the outstanding principal balance if prepaid more than one year but less than two years after October 17, 2019, or 1.0% of the outstanding principal balance if prepaid two years or more after October 17, 2019. Any amounts borrowed and repaid may not be reborrowed              
Amended Loan Agreement [Member] | Bank Warrant [Member]                    
Short-term Debt [Line Items]                    
Debt instrument, final payment     $ 200,000              
Unamortized deferred financing cost         22,000     22,000    
Warrants to purchase, shares     98,574              
Warrant exercise price, per share     $ 1.69              
Amended Loan Agreement [Member] | Share-based Payment Arrangement, Tranche One [Member]                    
Short-term Debt [Line Items]                    
Line of Credit, Current     $ 3,000,000              
Repayments of Lines of Credit     400,000              
Debt instrument, final payment     116,000              
Amended Loan Agreement [Member] | Share-based Payment Arrangement, Tranche Two [Member]                    
Short-term Debt [Line Items]                    
Line of Credit, Current     $ 2,000,000   $ 2,000,000     $ 2,000,000    
Line of credit, description     The credit line under the Amended Loan Agreement may be increased by an additional $2 million (“Tranche 2”) if Oncocyte obtains at least $20 million of additional equity capital, as was the case with the original Loan Agreement, and a positive final coverage determination is received from CMS for DetermaRx at a specified minimum price point per test (the “Tranche 2 Milestone”), and Oncocyte is not in default under the Amended Loan Agreement.              
Additional Paid in Capital     $ 20,000,000              
Interest rate     5.00%              
Amended Loan Agreement [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Bank Warrant [Member]                    
Short-term Debt [Line Items]                    
Percentage for warrant exercise price per share     0.02%              
Diluted equity outstanding     $ 1,000,000              
Loan Deferral Agreement [Member]                    
Short-term Debt [Line Items]                    
Debt instrument, maturity date description   Under the Loan Deferral Agreement, the Bank agreed to (i) extend the scheduled maturity date of the Amended Loan Agreement from March 31, 2022 to September 30, 2022, and (ii) deferred the principal payments by an additional 6 months whereby payments of interest only on the Bank loan principal balance will be due monthly from May 1, 2020 through October 1, 2020, followed by 23 monthly payments of principal and interest beginning on November 1, 2020, all provided at no additional fees to Oncocyte.                
Loan and Security Agreement [Member]                    
Short-term Debt [Line Items]                    
Amount borrowed       $ 2,000,000.0            
Debt instrument, maturity date       Apr. 01, 2020            
Amortization of deferred financing costs       $ 116,000            
Prepayment fee if prepaid two years or more       1.00%            
PPP [Member]                    
Short-term Debt [Line Items]                    
Amount borrowed $ 1,140,930                  
Debt instrument, maturity date Apr. 23, 2022                  
Debt instrument, interest rate 1.00%                  
Gain on extingushment of debt $ 1,140,930                  
Interest expense             $ 11,000